A5010056224- Chronic Obstructive Pulmonary Disease (COPD) Research
- Protease and Inhibitor Mechanisms
- Respiratory Support and Mechanisms
- Asthma and respiratory diseases
- Pulmonary Hypertension Research and Treatments
- Neonatal Respiratory Health Research
- Peptidase Inhibition and Analysis
- Cystic Fibrosis Research Advances
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Blood Coagulation and Thrombosis Mechanisms
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Pediatric health and respiratory diseases
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cell Adhesion Molecules Research
- S100 Proteins and Annexins
- Respiratory viral infections research
- Pleural and Pulmonary Diseases
- Immune Response and Inflammation
- Oral microbiology and periodontitis research
- Inflammation biomarkers and pathways
- Pneumonia and Respiratory Infections
- Congenital Diaphragmatic Hernia Studies
- Lung Cancer Diagnosis and Treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
University of Birmingham
2014-2025
University Hospitals Birmingham NHS Foundation Trust
2016-2025
Queen Elizabeth Hospital Birmingham
2016-2025
NIHR Surgical Reconstruction and Microbiology Research Centre
2012-2024
National Health Service
2007-2023
University College London
2023
Nottingham Biomedical Research Centre
2023
Queen Elizabeth Hospital
2016-2023
Centre for Inflammation Research
2014-2023
Queen Elizabeth Hospital
2002-2021
Section:ChooseTop of pageAbstract <<IntroductionDefinition and Factors Th...Diagnosis Initial Ass...Prevention Maintenanc...Rehabilitation, Education...Supportive, Palliative, E...Other TreatmentsInterventional TherapyManagement Stable COPDTreatment COPDMonitoring Follow-upTreatment OptionsCOPD ComorbiditiesReferencesCITING ARTICLES
Exacerbations are key drivers of morbidity and mortality in chronic obstructive pulmonary disease (COPD).We compared the relative efficacy long-acting inhaled bronchodilator/antiinflammatory combination (salmeterol/fluticasone propionate) 50/500 microg twice daily bronchodilator (tiotropium) 18 once preventing exacerbations related outcomes severe very COPD.A total 1,323 patients (mean age, 64 yr, post-bronchodilator FEV1, 39% predicted) were randomized this 2-year, double-blind,...
This Executive Summary of the Global Strategy for Diagnosis, Management, and Prevention COPD (GOLD) 2017 Report focuses primarily on revised novel parts document. The most significant changes include: 1) assessment chronic obstructive pulmonary disease has been refined to separate spirometric from symptom evaluation. ABCD groups are now proposed be derived exclusively patient symptoms their history exacerbations; 2) each A D, escalation strategies pharmacological treatments proposed; 3)...
<b>Executive summary of the Global Strategy for Prevention, Diagnosis and Management COPD 2023: latest evidence-based strategy document from Initiative Chronic Obstructive Lung Disease (GOLD</b><b>)</b> https://bit.ly/3KCaTGe
Inhalt Seite Zusammenfassung Einleitung 37 Ziele, Organisation des Projektes und Zeitplan der wichtigsten Empfehlungen Arbeitsgruppe zur Diagnose Behandlung Alpha-1-Antitrypsin-Mangel 38 Klinische Erkennung Alpha-1-Antitrypsin-Mangels Genetische Testung auf Lebererkrankungen 39 Andere Erkrankungen 40 Wirksamkeit Substitutionstherapie Allgemeines Management bei obstruktiver Atemwegserkrankung Literatur 41 Lungenerkrankung Erstellung dieses Dokuments Epidemiologie 42 Pathophysiologie...
This Executive Summary of the Global Strategy for Diagnosis, Management and Prevention COPD, Initiative Chronic Obstructive Lung Disease (GOLD) 2017 Report focuses primarily on revised novel parts document. The most significant changes include: (i) assessment chronic obstructive pulmonary disease has been refined to separate spirometric from symptom evaluation. ABCD groups are now proposed be derived exclusively patient symptoms their history exacerbations; (ii) each A D, escalation...
Assessment of emphysema-modifying therapy is difficult, but newer outcome measures offer advantages over traditional methods. The EXAcerbations and Computed Tomography scan as Lung End-points (EXACTLE) trial explored the use computed tomography (CT) densitometry exacerbations for assessment therapeutic effect augmentation in subjects with alpha(1)-antitrypsin (alpha(1)-AT) deficiency. In total, 77 (protease inhibitor type Z) were randomised to weekly infusions 60 mg x kg(-1) human...
Currently the diagnosis of chronic obstructive pulmonary disease (COPD) requires demonstration airflow limitation, defined as a post-bronchodilator FEV 1 /FVC <0.7, measurement that remains methodologically robust and widely available.FEV is one most powerful predictors clinically relevant outcomes including symptoms, exacerbations mortality.However, reliable data suggest respiratory in particular bronchitis, airway abnormality emphysema detected using modern imaging techniques such computed...
Chronic obstructive pulmonary disease (COPD) due to tobacco smoking commonly presents when extensive lung damage has occurred.
It has been suggested that proteinase enzymes could play an important role in the pathogenesis of chronic bronchial infections including bronchiectasis and cystic fibrosis (CF). Because Pseudomonas aeruginosa frequently colonizes respiratory tract CF, we examined vitro effects human neutrophil elastase (HNE) produced by P. (elastase: PE; alkaline proteinase: PAP) on ciliary beat frequency (CBF) ultrastructure nasal ciliated epithelium.HNE (500 µg/ml) progressively reduced CBF caused marked...